{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:47:50Z","timestamp":1758980870979,"version":"3.40.4"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl."],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00103-015-2253-z","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T23:00:19Z","timestamp":1445468419000},"page":"1314-1343","source":"Crossref","is-referenced-by-count":20,"title":["Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease","Wissenschaftliche Begr\u00fcndung zur Aktualisierung der Meningokokken-Impfempfehlung \u2013 Anwendung des Meningokokken-B-Impfstoffs bei Personen mit erh\u00f6htem Risiko f\u00fcr Meningokokken-Erkrankungen"],"prefix":"10.1007","volume":"58","author":[{"given":"Wiebke","family":"Hellenbrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Harder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bogdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Heininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Terhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"von Kries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"key":"2253_CR1","unstructured":"STIKO (2014) Standard Operating Procedure of the German Standing Committee on Vaccinations (STIKO) for the systematic development of vaccination recommendations. Version 2. February 6, 2014. http:\/\/www.rki.de\/DE\/Content\/Kommissionen\/STIKO\/Aufgaben_Methoden\/SOP.pdf?__blob=publicationFile. Accessed 1 Sept 2015"},{"issue":"11","key":"2253_CR2","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1017\/S0950268808000770","volume":"136","author":"M Hoek","year":"2008","unstructured":"Hoek M, Christensen H, Hellenbrand W, Stefanoff P, HOWITZ M, Stuart J (2008) Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review. Epidemiol Infect 136(11):1441\u20131447","journal-title":"Epidemiol Infect"},{"key":"2253_CR3","first-page":"314","volume":"137","author":"STIKO","year":"2009","unstructured":"STIKO (2009) Mitteilung der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Empfehlung und Begr\u00fcndung einer postexpositionellen Meningokokken-Impfung. Epid Bull 31:314\u2013317","journal-title":"Epid Bull"},{"issue":"4","key":"2253_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/jhin.2001.1084","volume":"49","author":"R Boutet","year":"2001","unstructured":"Boutet R, Stuart JM, Kaczmarski EB, Gray SJ, Jones DM, Andrews N (2001) Risk of laboratory-acquired meningococcal disease. J Hosp Infect 49(4):282\u2013284","journal-title":"J Hosp Infect"},{"issue":"9","key":"2253_CR5","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1128\/JCM.43.9.4811-4814.2005","volume":"43","author":"JJ Sejvar","year":"2005","unstructured":"Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, Weyant R, Stephens DS, Perkins BA, Rosenstein NE (2005) Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol 43(9):4811\u20134814","journal-title":"J Clin Microbiol"},{"key":"2253_CR6","volume-title":"Fachinformation (Zusammenfassung der Merkmale des Arzneimittels): Bexsero, Novartis Vaccines","author":"Rote Liste ServiceGmbH","year":"2014","unstructured":"Rote Liste ServiceGmbH (2014) Fachinformation (Zusammenfassung der Merkmale des Arzneimittels): Bexsero, Novartis Vaccines. Rote Liste ServiceGmbH, Frankfurt"},{"key":"2253_CR7","unstructured":"European Medicines Agency (2013) European Public Assessment Report: Bexsero In. London. http:\/\/www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Summary_for_the_public\/human\/002333\/WC500137857.pdf. Accessed 1 Sept 2015"},{"issue":"4","key":"2253_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1128\/CMR.00048-09","volume":"23","author":"S Ram","year":"2010","unstructured":"Ram S, Lewis LA, Rice PA (2010) Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 23(4):740\u2013780","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2253_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/viru.26515","volume":"5","author":"LA Lewis","year":"2014","unstructured":"Lewis LA, Ram S (2014) Meningococcal disease and the complement system. Virulence 5(1):98\u2013126","journal-title":"Virulence"},{"issue":"9","key":"2253_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/QAD.0b013e32833a2520","volume":"24","author":"C Cohen","year":"2010","unstructured":"Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, Meiring S, Govender N, von Gottberg A, for the Group for Enteric R et al (2010) Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 24(9):1351\u20131360","journal-title":"AIDS"},{"issue":"11\u201312","key":"2253_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S0264-410X(00)00333-9","volume":"19","author":"AJ Pollard","year":"2001","unstructured":"Pollard AJ, Frasch C (2001) Development of natural immunity to Neisseria meningitidis. Vaccine 19(11\u201312):1327\u20131346","journal-title":"Vaccine"},{"issue":"17\u201318","key":"2253_CR12","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.vaccine.2003.11.052","volume":"22","author":"H Kelly","year":"2004","unstructured":"Kelly H, Attia J, Andrews R, Heller RF (2004) The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 22(17\u201318):2192\u20132198","journal-title":"Vaccine"},{"issue":"4","key":"2253_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3201\/eid1904.111799","volume":"19","author":"OB Harrison","year":"2013","unstructured":"Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD et al (2013) Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 19(4):566\u2013573","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"2253_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL (2010) Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 10(12):853\u2013861","journal-title":"Lancet Infect Dis"},{"key":"2253_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1017\/S0950268898008930","volume":"121","author":"P Andersen","year":"1998","unstructured":"Andersen P, Berthelsen L, Bech Jensen B, Lind I (1998) Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. Epidemiol Infect 121:85\u201394","journal-title":"Epidemiol Infect"},{"key":"2253_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S0950268800029198","volume":"101","author":"JV Pether","year":"1988","unstructured":"Pether JV, Lightfoot NF, Scott RJ, Morgan J, Stelle-Perkins AP, Sheard SC (1988) Carriage of Neisseria meningitidis: investigations in a military establishment. Epidemiol Infect 101:21\u201342","journal-title":"Epidemiol Infect"},{"issue":"9","key":"2253_CR17","first-page":"1761","volume":"17","author":"DAA Ala\u2019Aldeen","year":"2011","unstructured":"Ala\u2019Aldeen DAA, Oldfield NJ, Bidmos FA, Abouseada NA, Ahmed NW, Turner DPJ, Neal KR, Bayliss CD (2011) Carriage of meningococci by university students, United Kingdom [letter]. Emerg Infect Dis 17(9):1761\u20131763","journal-title":"Emerg Infect Dis"},{"key":"2253_CR18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1086\/428590","volume":"191","author":"H Claus","year":"2005","unstructured":"Claus H, Maiden MJC, Wilson DJ, McCarthy NDJ, Urwin R, Hessler F, Frosch M, Vogel U (2005) Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191:1263\u20131271","journal-title":"J Infect Dis"},{"issue":"1","key":"2253_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2105\/AJPH.71.1.53","volume":"71","author":"YC Faur","year":"1981","unstructured":"Faur YC, Wilson ME, May PS (1981) Isolation of N. meningitidis from patients in a gonorrhea screen program: a four-year survey in New York City. Am J Public Health 71(1):53\u201358","journal-title":"Am J Public Health"},{"issue":"18","key":"2253_CR20","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1001\/jama.1980.03310180026026","volume":"244","author":"WM Janda","year":"1980","unstructured":"Janda WM, Bohnhoff M, Morello JA, Lerner SA (1980) Prevalence and site-pathogen studies of Neisseria meningitidis and N. gonorrhoeae in homosexual men. JAMA 244(18):2060\u20132064","journal-title":"JAMA"},{"issue":"2","key":"2253_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/ije\/dyi295","volume":"35","author":"PG Coen","year":"2006","unstructured":"Coen PG, Tully J, Stuart JM, Ashby D, Viner RM, Booy R (2006) Is it exposure to cigarette smoke or to smokers which increases the risk of meningococcal disease in teenagers? Int J Epidemiol 35(2):330\u2013336","journal-title":"Int J Epidemiol"},{"key":"2253_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1445-5994.2004.00564.x","volume":"34","author":"BJ McCall","year":"2004","unstructured":"McCall BJ, Neill AS, Young MM (2004) Risk factors for invasive meningococcal disease in southern Queensland, 2000\u20132001. Intern Med J 34:464\u2013468","journal-title":"Intern Med J"},{"issue":"2","key":"2253_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/clinids\/14.2.515","volume":"14","author":"PS Moore","year":"1992","unstructured":"Moore PS (1992) Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process. Clin Infect Dis 14(2):515\u2013525","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2253_CR24","doi-asserted-by":"publisher","first-page":"e15493","DOI":"10.1371\/journal.pone.0015493","volume":"5","author":"AR Tuite","year":"2010","unstructured":"Tuite AR, Kinlin LM, Kuster SP, Jamieson F, Kwong JC, McGeer A, Fisman DN (2010) Respiratory virus infection and risk of invasive meningococcal disease in Central Ontario, Canada. PLoS One 5(11):e15493","journal-title":"PLoS One"},{"key":"2253_CR25","unstructured":"Robert Koch-Institut (2014) Meningokokken-Erkrankungen. Ratgeber Infektionskrankheiten\u2014Merkbl\u00e4tter f\u00fcr \u00c4rzte [Meningococcal disease. Guidance on infectious disease for Physicians]. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Merkblaetter\/Ratgeber_Meningokokken.html. Accessed 1 Sept 2015"},{"issue":"1","key":"2253_CR26","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","volume":"32","author":"JA Bettinger","year":"2013","unstructured":"Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, for the Members of the Canadian Immunization Monitoring Program A (2013) The Disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 32(1):e20\u2013e25. doi:10.1097\/INF.0b013e3182706b89","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2253_CR27","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1093\/cid\/cir500","volume":"53","author":"M Gottfredsson","year":"2011","unstructured":"Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, Sigurdsson JF, Schneerson R, Robbins JB, Miller MA (2011) Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis 53(9):e117\u2013e124","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2253_CR28","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1017\/S0950268809002428","volume":"137","author":"M Howitz","year":"2009","unstructured":"Howitz M, Lambertsen L, Simonsen JB, Christensen JJ, M\u00f8lbak K (2009) Morbidity, mortality and spatial distribution of meningococcal disease, 1974\u20132007. Epidemiol Infect 137(11):1631\u20131640","journal-title":"Epidemiol Infect"},{"issue":"9","key":"2253_CR29","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D (2012) Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 11(9):774\u2013783","journal-title":"Lancet Neurol"},{"key":"2253_CR30","unstructured":"European Centre for Disease Prevention and Control (2013) Surveillance of invasive bacterial diseases in Europe 2011. In. Stockholm. Accessed 1 Sept 2015"},{"key":"2253_CR31","unstructured":"European Medicines Agency (2012) Summary of opinion (initial authorisation) Bexsero Meningococcal group B Vaccine (rDNA, component, adsorbed). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002333\/WC500134836.pdf. Accessed 1 Sept 2015"},{"issue":"3","key":"2253_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0968-0004(85)90274-9","volume":"10","author":"J Finne","year":"1985","unstructured":"Finne J (1985) Polysialic acid\u2014a glycoprotein carbohydrate involved in neural adhesion and bacterial meningitis. Trends Biochem Sci 10(3):129\u2013132","journal-title":"Trends Biochem Sci"},{"issue":"5459","key":"2253_CR33","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","author":"M Pizza","year":"2000","unstructured":"Pizza M, Scarlato V, Masignani V, Giuliani MM, Aric\u00f2 B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B et al (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459):1816\u20131820","journal-title":"Science"},{"issue":"40","key":"2253_CR34","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","volume":"29","author":"R Arnold","year":"2011","unstructured":"Arnold R, Galloway Y, McNicholas A, O\u2019Hallahan J (2011) Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 29(40):7100\u20137106","journal-title":"Vaccine"},{"issue":"6","key":"2253_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2012.85","volume":"307","author":"N Gossger","year":"2012","unstructured":"Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B et al (2012) Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307(6):573\u2013582","journal-title":"JAMA"},{"issue":"8","key":"2253_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1586\/14760584.2013.814862","volume":"12","author":"NG Martin","year":"2013","unstructured":"Martin NG, Snape MD (2013) A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines 12(8):837\u2013858","journal-title":"Expert Rev Vaccines"},{"issue":"9869","key":"2253_CR37","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"T Vesikari","year":"2013","unstructured":"Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 381(9869):825\u2013835","journal-title":"Lancet"},{"issue":"29","key":"2253_CR38","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1016\/j.vaccine.2015.05.027","volume":"33","author":"J Findlow","year":"2015","unstructured":"Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R (2015) Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine 33(29):3322\u20133330","journal-title":"Vaccine"},{"issue":"1","key":"2253_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1586\/14760584.3.1.77","volume":"3","author":"P Balmer","year":"2004","unstructured":"Balmer P, Borrow R (2004) Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines 3(1):77\u201387","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"2253_CR40","doi-asserted-by":"publisher","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch CE, Borrow R, Donnelly J (2009) Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl 2):B112\u2013B116","journal-title":"Vaccine"},{"issue":"45","key":"2253_CR41","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","author":"J Donnelly","year":"2010","unstructured":"Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S et al (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 107(45):19490\u201319495","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2253_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","volume":"13","author":"U Vogel","year":"2013","unstructured":"Vogel U, Taha M-K, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S et al (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13(5):416\u2013425","journal-title":"Lancet Infect Dis"},{"key":"2253_CR43","unstructured":"Claus H, Vogel U, De Paola R, Stella M, Wichmann O, Hellenbrand W (2014) Meningococcal antigen typing system (MATS) based coverage for Bexsero on invasive MenB strains isolated from infants aged less than one year in Germany 2007\u20132013. In: International Pathogenic Neisseria Conference. Asheville, North Carolina"},{"issue":"9816","key":"2253_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","volume":"379","author":"ME Santolaya","year":"2012","unstructured":"Santolaya ME, O\u02bcRyan ML, Valenzuela MT, Prado V, Vergara R, Mu\u00f1oz A, Toneatto D, Gra\u00f1a G, Wang H, Clemens R et al (2012) Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet 379(9816):617\u2013624","journal-title":"Lancet"},{"issue":"7","key":"2253_CR45","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/INF.0000000000000327","volume":"33","author":"F McQuaid","year":"2014","unstructured":"McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Houlden J, Voysey M, Toneatto D, Kitte C, Dull PM et al (2014) Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J 33(7):760\u2013766. doi:10.1097\/INF.0000000000000327","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"2253_CR46","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/INF.0b013e31829cfff2","volume":"32","author":"MD Snape","year":"2013","unstructured":"Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, Yu L-M, Kittel C, Toneatto D, Dull PM et al (2013) Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J 32(10):1116\u20131121. doi:10.1097\/INF.0b013e31829cfff2","journal-title":"Pediatr Infect Dis J"},{"issue":"15","key":"2253_CR47","doi-asserted-by":"publisher","first-page":"E715","DOI":"10.1503\/cmaj.130257","volume":"185","author":"MD Snape","year":"2013","unstructured":"Snape MD, Saroey P, John TM, Robinson H, Kelly S, Gossger N, Yu L-M, Wang H, Toneatto D, Dull PM et al (2013) Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. Can Med Assoc J 185(15):E715\u2013E724","journal-title":"Can Med Assoc J"},{"issue":"11","key":"2253_CR48","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.4161\/hv.25505","volume":"9","author":"ME Santolaya","year":"2013","unstructured":"Santolaya ME, O\u2019Ryan M, Valenzuela MT, Prado V, Vergara RF, Mu\u00f1oz A, Toneatto D, Gra\u00f1a G, Wang H, Dull PM (2013) Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 9(11):2304\u20132310","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"2253_CR49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"M Maiden","year":"2008","unstructured":"Maiden M, Ibarz-Pavon A, Urwin R, Gray S, Andrews N, Clarke S, Walker AM, Evans M, Kroll JS, Neal K et al (2008) Impact of meningococcal serogroup c conjugate vaccines on carriage and herd immunity. J Infect Dis 197(5):737\u2013743","journal-title":"J Infect Dis"},{"issue":"5","key":"2253_CR50","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/CVI.00529-09","volume":"17","author":"H Campbell","year":"2010","unstructured":"Campbell H, Andrews N, Borrow R, Trotter C, Miller E (2010) Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modelling predictions of the duration of herd immunity. Clin Vacc Immunol 17(5):840\u2013847","journal-title":"Clin Vacc Immunol"},{"issue":"2","key":"2253_CR51","doi-asserted-by":"publisher","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","volume":"27","author":"H Campbell","year":"2009","unstructured":"Campbell H, Borrow R, Salisbury D, Miller E (2009) Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl 2):B20\u2013B29","journal-title":"Vaccine"},{"key":"2253_CR52","unstructured":"Read R, Baxter D, Chadwick D, Faust S (2013) Impact of a quadrivalent conjugate (MENACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. In: The 31st Meeting of the European Society for Paediatric Infectious Diseases: 2013; Milan, Italy"},{"key":"2253_CR53","unstructured":"De Serres G, Gari\u00e9py M-C, Billard M-N, Rouleau I (2014) Rapport int\u00e9rimaire de surveillance de la s\u00e9curit\u00e9 de la premi\u00e8re dose du vaccin contre le m\u00e9ningocoque de s\u00e9rogroupe B au Saguenay\u2014Lac-Saint-Jean. In. Edited by Institut nationale sant\u00e9 publique du Qu\u00e9bec. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCAQFjAAahUKEwjk0f_jrZnIAhVCPRQKHeIkDnY&url=https%3A%2F%2Fwww.inspq.qc.ca%2Fpdf%2Fpublications%2F1885_Vaccin_Menincogoque_SerogroupeB.pdf&usg=AFQjCNEKfOTJVE4CaEiwaEUGevc084wLdQ. Accessed 1 Sept 2015"},{"issue":"1","key":"2253_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","volume":"160","author":"L Miller","year":"2014","unstructured":"Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J, Steiner-Sichel L, Ngai S, Shepard C, Weiss D (2014) Elevated Risk for Invasive Meningococcal Disease Among Persons With HIV. Ann Intern Med 160(1):30\u201337","journal-title":"Ann Intern Med"},{"issue":"6","key":"2253_CR55","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1089\/sur.2013.051","volume":"15","author":"LU Taniguchi","year":"2014","unstructured":"Taniguchi LU, Correia MD, Zampieri FG (2014) Overwhelming postsplenectomy infection: narrative review of the literature. Surg Infect 15(6):686\u2013693","journal-title":"Surg Infect (Larchmt)"},{"issue":"6","key":"2253_CR56","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/bjs.1800780626","volume":"78","author":"GL Cullingford","year":"1991","unstructured":"Cullingford GL, Watkins DN, Watts ADJ, Mallon DF (1991) Severe late postsplenectomy infection. Br J Surg 78(6):716\u2013721","journal-title":"Br J Surg"},{"issue":"5","key":"2253_CR57","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/003655400458811","volume":"32","author":"P Ejstrud","year":"2000","unstructured":"Ejstrud P, Kristensen B, Hansen JB, Madsen KM, Schonheyder HC, Sorensen HT (2000) Risk and patterns of bacteraemia after splenectomy: a population-based study. Scand J Infect Dis 32(5):521\u2013525","journal-title":"Scand J Infect Dis"},{"key":"2253_CR58","doi-asserted-by":"crossref","first-page":"582","DOI":"10.5694\/mja11.10909","volume":"196","author":"C Dendle","year":"2012","unstructured":"Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I (2012) Splenectomy sequelae: an analysis of infectious outcomes among adults in Victoria. Med J Aust 196:582\u2013586","journal-title":"Med J Aust"},{"issue":"8","key":"2253_CR59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.7326\/0003-4819-151-8-200910200-00008","volume":"151","author":"RW Thomsen","year":"2009","unstructured":"Thomsen RW, Schoonen WM, Farkas DrK, Riis A, Jacobsen J, Fryzek JP, S\u00f8rensen HT (2009) Risk for hospital contact with infection in patients with splenectomy a population-based cohort study. Ann Intern Med 151(8):546\u2013555","journal-title":"Ann Intern Med"},{"issue":"3","key":"2253_CR60","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/jcp.54.3.214","volume":"54","author":"DJ Waghorn","year":"2001","unstructured":"Waghorn DJ (2001) Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 54(3):214\u2013218","journal-title":"J Clin Pathol"},{"issue":"9","key":"2253_CR61","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/bjs.1800780904","volume":"78","author":"RJ Holdsworth","year":"1991","unstructured":"Holdsworth RJ, Cuschieri A, Irving AD (1991) Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg 78(9):1031\u20131038","journal-title":"Br J Surg"},{"issue":"3","key":"2253_CR62","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/j.amjmed.2005.07.044","volume":"119","author":"MH Kyaw","year":"2006","unstructured":"Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, Campbell H (2006) Evaluation of severe infection and survival after splenectomy. Am J Med 119(3):276.e271\u2013276.e277","journal-title":"Am J Med"},{"issue":"3","key":"2253_CR63","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/jinf.2001.0904","volume":"43","author":"N Bisharat","year":"2001","unstructured":"Bisharat N, Omari H, Lavi I, Raz R (2001) Risk of infection and death among post-splenectomy patients. J Infect 43(3):182\u2013186","journal-title":"J Infect"},{"issue":"4","key":"2253_CR64","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0022-3468(86)80195-6","volume":"21","author":"BW Loggie","year":"1986","unstructured":"Loggie BW, John Hinchey E (1986) Does splenectomy predispose to meningococcal sepsis? An experimental study and clinical review. J Pediatr Surg 21(4):326\u2013330","journal-title":"J Pediatr Surg"},{"key":"2253_CR65","unstructured":"Statistisches Bundesamt (2014) DRG-Statistiken des Statistischen Bundesamtes. In. Edited by https:\/\/www.gbe-bund.de\/gbe10\/abrechnung.prc_abr_test_logon?p_uid=gast&p_aid=0&p_knoten=VR&p_sprache=D&p_suchstring=splenektomie. Accessed 1 Sept 2015 Statistisches Bundesamt, Wiesbaden"},{"key":"2253_CR66","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/cei.12105","volume":"173","author":"B Gathmann","year":"2013","unstructured":"Gathmann B, Goldacker S, Klima M, Belohradsky BH, Notheis G, Ehl S, Ritterbusch H, Baumann U, Meyer-Bahlburg A, Witte T et al (2013) The German national registry for primary immunodeficiencies (PID). Clin Exp Immunol 173:372\u2013380","journal-title":"Clin Exp Immunol"},{"issue":"09","key":"2253_CR67","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1055\/s-0034-1369813","volume":"139","author":"S Eber","year":"2014","unstructured":"Eber S, Dickerhoff R (2014) An\u00e4mien und H\u00e4moglobinkrankheiten bei Patienten mit Migrationshintergrund. Dtsch Med Wochenschr 139(09):434\u2013440","journal-title":"Dtsch Med Wochenschr"},{"issue":"5","key":"2253_CR68","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10096-010-1129-2","volume":"30","author":"A Meerveld-Eggink","year":"2011","unstructured":"Meerveld-Eggink A, de Weerdt O, de Voer R, Berbers G, van Velzen-Blad H, Vlaminckx B, Biesma D, Rijkers G (2011) Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients. Eur J Clin Microbiol Infect Dis 30(5):611\u2013618","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"2253_CR69","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","volume":"72","author":"P Balmer","year":"2004","unstructured":"Balmer P, Falconer M, McDonald P, Andrews N, Fuller E, Riley C, Kaczmarski E, Borrow R (2004) Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 72(1):332\u2013337","journal-title":"Infect Immun"},{"issue":"4","key":"2253_CR70","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/bjs.6008","volume":"95","author":"GA Stoehr","year":"2008","unstructured":"Stoehr GA, Luecken J, Zielen S, Eber SW, Borrow R, Rose MA (2008) Mode of splenectomy and immunogenicity of meningococcal vaccination in patients with hereditary spherocytosis. Br J Surg 95(4):466\u2013471","journal-title":"Br J Surg"},{"issue":"10","key":"2253_CR71","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1517\/14712598.2013.824419","volume":"13","author":"R Mitchell","year":"2013","unstructured":"Mitchell R, Tr\u00fcck J, Pollard AJ (2013) Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6\u201317 years. Expert Opin Biol Ther 13(10):1451\u20131465","journal-title":"Expert Opin Biol Ther"},{"key":"2253_CR72","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-2334-10-219","volume":"10","author":"JM Langley","year":"2010","unstructured":"Langley JM, Dodds L, Fell D, Langley GR (2010) Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990\u20132002. BMC Infect Dis 10:219","journal-title":"BMC Infect Dis"},{"key":"2253_CR73","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","volume":"364","author":"CL Trotter","year":"2004","unstructured":"Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365\u2013367","journal-title":"Lancet"},{"issue":"3","key":"2253_CR74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","volume":"4","author":"JE Figueroa","year":"1991","unstructured":"Figueroa JE, Densen P (1991) Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4(3):359\u2013395","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"2253_CR75","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/00005792-199311000-00002","volume":"72","author":"AE Platonov","year":"1993","unstructured":"Platonov AE, Beloborodov VB, Vershinina IV (1993) Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine (Baltimore) 72(6):374\u2013392","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2253_CR76","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00005792-198409000-00001","volume":"63","author":"SC Ross","year":"1984","unstructured":"Ross SC, Densen P (1984) Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63(5):243\u2013273","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl","key":"2253_CR77","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1128\/CMR.2.Suppl.S11","volume":"2","author":"P Densen","year":"1989","unstructured":"Densen P (1989) Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin Microbiol Rev 2(Suppl):S11\u2013S17","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2253_CR78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02918259","volume":"12","author":"J Figueroa","year":"1993","unstructured":"Figueroa J, Andreoni J, Densen P (1993) Complement deficiency states and meningococcal disease. Immunol Res 12(3):295\u2013311","journal-title":"Immunol Res"},{"issue":"1","key":"2253_CR79","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1086\/515075","volume":"28","author":"CAP Fijen","year":"1999","unstructured":"Fijen CAP, Kuijper EJ, te Bulte MT, Daha MR, Dankert J (1999) Assessment of complement deficiency in patients with meningococcal disease in the Netherlands. Clin Infect Dis 28(1):98\u2013105","journal-title":"Clin Infect Dis"},{"issue":"8663","key":"2253_CR80","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0140-6736(89)90712-5","volume":"334","author":"CP Fijen","year":"1989","unstructured":"Fijen CP, Hannema A, Kuijper E, Sj\u00f6holm A, Van Putten JM (1989) Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet 334(8663):585\u2013588","journal-title":"Lancet"},{"issue":"9","key":"2253_CR81","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/jcm.32.9.2185-2191.1994","volume":"32","author":"A Orren","year":"1994","unstructured":"Orren A, Caugant DA, Fijen CA, Dankert J, van Schalkwyk EJ, Poolman JT, Coetzee GJ (1994) Characterization of strains of Neisseria meningitidis recovered from complement-sufficient and complement-deficient patients in the Western Cape Province, South Africa. J Clin Microbiol 32(9):2185\u20132191","journal-title":"J Clin Microbiol"},{"issue":"8","key":"2253_CR82","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1128\/JCM.36.8.2342-2345.1998","volume":"36","author":"CAP Fijen","year":"1998","unstructured":"Fijen CAP, Kuijper EJ, Dankert J, Daha MR, Caugant DA (1998) Characterization of Neisseria meningitidis strains causing disease in complement-deficient and complement-sufficient patients. J Clin Microbiol 36(8):2342\u20132345","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2253_CR83","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1744-313X.2012.01095.x","volume":"39","author":"DT Bradley","year":"2012","unstructured":"Bradley DT, Bourke TW, Fairley DJ, Borrow R, Shields MD, Young IS, Zipfel PF, Hughes AE (2012) Genetic susceptibility to invasive meningococcal disease: MBL2 structural polymorphisms revisited in a large case\u2014control study and a systematic review. Int J Immunogenet 39(4):328\u2013337","journal-title":"Int J Immunogenet"},{"issue":"14","key":"2253_CR84","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.molimm.2011.05.001","volume":"48","author":"L Skattum","year":"2011","unstructured":"Skattum L, van Deuren M, van der Poll T, Truedsson L (2011) Complement deficiency states and associated infections. Mol Immunol 48(14):1643\u20131655","journal-title":"Mol Immunol"},{"issue":"1\u20132","key":"2253_CR85","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.molimm.2005.06.025","volume":"43","author":"AG Sj\u00f6holm","year":"2006","unstructured":"Sj\u00f6holm AG, J\u00f6nsson G, Braconier JH, Sturfelt G, Truedsson L (2006) Complement deficiency and disease: an update. Mol Immunol 43(1\u20132):78\u201385","journal-title":"Mol Immunol"},{"issue":"2","key":"2253_CR86","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.molimm.2014.06.030","volume":"61","author":"AS Grumach","year":"2014","unstructured":"Grumach AS, Kirschfink M (2014) Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol 61(2):110\u2013117","journal-title":"Mol Immunol"},{"issue":"4","key":"2253_CR87","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1159\/000161504","volume":"27","author":"A H\u00e4ssig","year":"1964","unstructured":"H\u00e4ssig A, Borel JF, Ammann P, Th\u00f6ni M, B\u00fctler R (1964) Essentielle Hypokomplement\u00e4mie. Pathobiology 27(4):542\u2013547","journal-title":"Pathobiology"},{"key":"2253_CR88","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2249.2011.04542.x","volume":"167","author":"B Gathmann","year":"2011","unstructured":"Gathmann B, Binder N, Ehl S, Kindle G, ESID WOrking Party (2011) The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clin Exp Immunol 167:479\u2013491","journal-title":"Clin Exp Immunol"},{"key":"2253_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-43487-1","volume-title":"Arzneiverordnungs-Report 2014: Aktuelle Daten, Kosten, Trends und Kommentare","author":"U Schwabe","year":"2014","unstructured":"Schwabe U, Paffrath D (2014) Arzneiverordnungs-Report 2014: Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin"},{"issue":"2","key":"2253_CR90","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/infdis\/170.2.449","volume":"170","author":"M Schlesinger","year":"1994","unstructured":"Schlesinger M, Greenberg R, Levy J, Kayhty H, Levy R (1994) Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency. J Infect Dis 170(2):449\u2013453","journal-title":"J Infect Dis"},{"issue":"6","key":"2253_CR91","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1365-3083.1993.tb01677.x","volume":"37","author":"R Biselli","year":"1993","unstructured":"Biselli R, Casapollo I, D\u02bcAmelio R, Salvato S, Matricardi PM, Brai M (1993) Antibody response to meningococcal polysaccharides A and C in patients with complement defects. Scand J Immunol 37(6):644\u2013650","journal-title":"Scand J Immunol"},{"issue":"1","key":"2253_CR92","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/infdis\/168.1.227","volume":"168","author":"J Andreoni","year":"1993","unstructured":"Andreoni J, K\u00e4yhty H, Densen P (1993) Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J Infect Dis 168(1):227\u2013231","journal-title":"J Infect Dis"},{"issue":"3","key":"2253_CR93","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1046\/j.1365-2249.1998.00738.x","volume":"114","author":"CAP Fijen","year":"1998","unstructured":"Fijen CAP, Kuijper EJ, Drogari-Apiranthitou M, Van Leeuwen Y, Daha MR, Dankert J (1998) Protection against meningococcal serogroup ACYW disease in complement- deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 114(3):362\u2013369","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2253_CR94","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1159\/000070219","volume":"130","author":"AE Platonov","year":"2003","unstructured":"Platonov AE, Vershinina IV, K\u00e4yhty H, Fijen CAP, W\u00fcrzner R, Kuijper EJ (2003) Antibody-dependent killing of meningococci by human neutrophils in serum of late complement component-deficient patients. Int Arch Allergy Immunol 130(4):314\u2013321","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"2253_CR95","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2249.1995.tb03600.x","volume":"100","author":"AE Platonov","year":"1995","unstructured":"Platonov AE, Beloborodov VB, Pavlova LI, Vershinina IV, K\u00c4Yhty H (1995) Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 100(1):32\u201339","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2253_CR96","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1128\/CVI.00036-08","volume":"15","author":"JS Plested","year":"2008","unstructured":"Plested JS, Granoff DM (2008) Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 15(5):799\u2013804","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"2253_CR97","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1128\/CVI.00007-09","volume":"16","author":"JS Plested","year":"2009","unstructured":"Plested JS, Welsch JA, Granoff DM (2009) Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 16(6):785\u2013791","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"2253_CR98","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/infdis\/155.6.1266","volume":"155","author":"SC Ross","year":"1987","unstructured":"Ross SC, Rosenthal PJ, Berberich HM, Densen P (1987) Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis 155(6):1266\u20131275","journal-title":"J Infect Dis"},{"issue":"12","key":"2253_CR99","doi-asserted-by":"publisher","first-page":"937","DOI":"10.7326\/0003-4819-123-12-199512150-00007","volume":"123","author":"DS Stephens","year":"1995","unstructured":"Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM (1995) Sporadic meningococcal disease in adults: results of a 5-Year population-based study. Ann Intern Med 123(12):937\u2013940","journal-title":"Ann Intern Med"},{"issue":"1","key":"2253_CR100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","volume":"31","author":"GK Siberry","year":"2012","unstructured":"Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J et al (2012) Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J 31(1):47\u201352","journal-title":"Pediatr Infect Dis J"},{"issue":"37","key":"2253_CR101","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.vaccine.2012.06.069","volume":"30","author":"DV Bertolini","year":"2012","unstructured":"Bertolini DV, Costa LS, van der Heijden IM, Sato HK, de Sousa Marques HH (2012) Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults. Vaccine 30(37):5482\u20135486","journal-title":"Vaccine"},{"key":"2253_CR102","doi-asserted-by":"crossref","unstructured":"Frota ACC, Milagres LG, Harrison LH, Ferreira B, Barreto DM, Pereira GS, Cruz AC, Pereira-Manfro W, de Oliveira RH, Abreu TF et al (2014) Immunogenicity and safety of meningococcal C Conjugate Vaccine in children and adolescents infected and uninfected with human immunodeficiency virus in Rio de Janeiro, Brazil. Pediatr Infect Dis J 34(5)e113\u2013e118","DOI":"10.1097\/INF.0000000000000630"},{"issue":"4","key":"2253_CR103","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","volume":"161","author":"J Lujan-Zilbermann","year":"2012","unstructured":"Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P et al (2012) Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr 161(4):676\u2013681.e672","journal-title":"J Pediatr"},{"issue":"5","key":"2253_CR104","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","volume":"29","author":"GK Siberry","year":"2010","unstructured":"Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P et al (2010) Phase I\/II, Open-label trial of safety and immunogenicity of meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 29(5):391\u2013396","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"2253_CR105","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/apc.2014.0121","volume":"28","author":"NF Crum-Cianflone","year":"2014","unstructured":"Crum-Cianflone NF, Wallace MR (2014) Vaccination in HIV-Infected Adults. Aids Patient Care STDS 28(8):397\u2013410","journal-title":"Aids Patient Care STDS"},{"issue":"11","key":"2253_CR106","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/jcp.2005.031054","volume":"59","author":"S Lear","year":"2005","unstructured":"Lear S, Eren E, Findlow J, Borrow R, Webster D, Jolles S (2005) Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin. J Clin Pathol 59(11):1191\u20131193","journal-title":"J Clin Pathol"},{"issue":"30","key":"2253_CR107","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1016\/j.vaccine.2014.05.022","volume":"32","author":"N Principi","year":"2014","unstructured":"Principi N, Esposito S (2014) Vaccine use in primary immunodeficiency disorders. Vaccine 32(30):3725\u20133731","journal-title":"Vaccine"},{"issue":"3","key":"2253_CR108","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.clim.2007.04.011","volume":"124","author":"S Goldacker","year":"2007","unstructured":"Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J, Eibel H, Schlesier M, Peter HH (2007) Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 124(3):294\u2013303","journal-title":"Clin Immunol"},{"issue":"1","key":"2253_CR109","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clim.2005.03.019","volume":"116","author":"J Ko","year":"2005","unstructured":"Ko J, Radigan L, Cunningham-Rundles C (2005) Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol 116(1):37\u201341","journal-title":"Clin Immunol"},{"issue":"4","key":"2253_CR110","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1128\/CVI.00489-07","volume":"15","author":"N Rezaei","year":"2008","unstructured":"Rezaei N, Aghamohammadi A, Siadat SD, Moin M, Pourpak Z, Nejati M, Ahmadi H, Kamali S, Norouzian D, Tabaraei B et al (2008) Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin Vacc Immunol 15(4):607\u2013611","journal-title":"Clin Vacc Immunol"},{"issue":"1","key":"2253_CR111","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0163-4453(81)80009-6","volume":"3","author":"P De Wals","year":"1981","unstructured":"De Wals P, Hertoghe L, Borle\u00e9-Grim\u00e9e I, De Mayer-Cleempel S, Reginster-Haneuse G, Dachy A, Bouckaert A, Lechat MF (1981) Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J Infect 3(Suppl 1):53\u201361","journal-title":"J Infect"},{"issue":"3","key":"2253_CR112","first-page":"261","volume":"235","author":"Group TMDS","year":"1974","unstructured":"Group TMDS (1974) Meningococcal disease. Secondary attack rate and chemoprophylaxis in the United States, 1974. J Am Med Assoc 235(3):261\u2013265","journal-title":"J Am Med Assoc"},{"key":"2253_CR113","unstructured":"European Centre for Disease Prevention and Control (2010) Public health management of sporadic cases of invasive meningococcal disease and their contacts. In. Edited by http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/Forms\/ECDC_DispForm.aspx?ID=572 Eao. Stockhom. Accessed 1 Sept 2015"},{"issue":"5","key":"2253_CR114","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jinf.2014.07.002","volume":"69","author":"SN Ladhani","year":"2014","unstructured":"Ladhani SN, Cordery R, Mandal S, Christensen H, Campbell H, Borrow R, Ramsay ME (2014) Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero\u00ae). J Infect 69(5):470\u2013480","journal-title":"J Infect"},{"key":"2253_CR115","unstructured":"Ladhani SN, Cordery R, Mandal S, Christensen H, Campbell H, Borrow R, Ramsay M (2014) PHE VaPiBi forum members: preventing secondary cases of invasive meningococcal capsular group B (MenB) disease: benefits of offering vaccination in addition to antibiotic chemoprophylaxis to close contacts of cases in the household, educational setting, clusters and the wider community. In., vol. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/328835\/Invasive_meningococcus_secondary_case_prevention_April_2014.pdf. Public Helath England, London"},{"issue":"7","key":"2253_CR116","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.4161\/hv.28666","volume":"10","author":"R Prymula","year":"2014","unstructured":"Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM (2014) A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. Hum Vaccin Immunother 10(7):1993\u20132004","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"2253_CR117","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jinf.2014.01.003","volume":"68","author":"R Borrow","year":"2014","unstructured":"Borrow R, Findlow J, Gray S, Taylor S, Kaczmarski E (2014) Safe laboratory handling of Neisseria meningitidis. J Infect 68(4):305\u2013312","journal-title":"J Infect"},{"issue":"3","key":"2253_CR118","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/jcm.32.3.701-704.1994","volume":"32","author":"M Guibourdenche","year":"1994","unstructured":"Guibourdenche M, Darchis JP, Boisivon A, Collatz E, Riou JY (1994) Enzyme electrophoresis, sero- and subtyping, and outer membrane protein characterization of two Neisseria meningitidis strains involved in laboratory-acquired infections. J Clin Microbiol 32(3):701\u2013704","journal-title":"J Clin Microbiol"},{"issue":"35","key":"2253_CR119","first-page":"770","volume":"63","author":"DS Channing","year":"2014","unstructured":"Channing DS, Harriman K, Zipprich J, Louie JK, Probert WS, Horowitz M, Prudhomme JC, Gold D, Mayer L (2014) Fatal meningococcal disease in a laboratory worker\u2014California, 2012. Morb Mortal Weekly Rep 63(35):770\u2013772","journal-title":"Morb Mortal Weekly Rep"},{"issue":"5","key":"2253_CR120","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1539\/joh.49.399","volume":"49","author":"AT Kessler","year":"2007","unstructured":"Kessler AT, Stephens DS, Somani J (2007) Laboratory-acquired serogroup A meningococcal meningitis. J Occup Health 49(5):399\u2013401","journal-title":"J Occup Health"},{"issue":"11","key":"2253_CR121","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","volume":"29","author":"MD Snape","year":"2010","unstructured":"Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E et al (2010) Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29(11):e71\u2013e79","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2253_CR122","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.4161\/hv.29218","volume":"10","author":"S Esposito","year":"2014","unstructured":"Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, Toneatto D (2014) A phase 2 II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II): effects of variations of the OMV and protein content on immunogenicity and reactogenicity. Hum Vaccin Immunother 10(7):2005\u20132014","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"2253_CR123","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1086\/656741","volume":"51","author":"J Findlow","year":"2010","unstructured":"Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D et al (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51(10):1127\u20131137","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2253_CR124","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4161\/hv.7.6.15482","volume":"7","author":"D Toneatto","year":"2011","unstructured":"Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P (2011) The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 7(6):646\u2013653","journal-title":"Hum Vaccin"},{"issue":"7","key":"2253_CR125","doi-asserted-by":"publisher","first-page":"781","DOI":"10.4161\/hv.7.7.15997","volume":"7","author":"D Toneatto","year":"2011","unstructured":"Toneatto D, Oster P, deBoer ACW, Emerson A, Santos GF, Ypma E, DeTora L, Pizza M, Kimura A, Dull P (2011) Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 7(7):781\u2013791","journal-title":"Hum Vaccin"},{"issue":"3","key":"2253_CR126","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"A Kimura","year":"2011","unstructured":"Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P (2011) Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vacc Immunol 18(3):483\u2013486","journal-title":"Clin Vacc Immunol"},{"issue":"9960","key":"2253_CR127","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJM, Pollard AJ, Turner DPJ et al (2014) Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 384(9960):2123\u20132131","journal-title":"Lancet"},{"key":"2253_CR128","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/adc.2010.188243","volume":"96","author":"Anonymous","year":"2011","unstructured":"Vesikari T, Esposito S, Prymula R, Ypma E, Kleinschmidt A, Toneatto D, Kimura A, Dull P (2011) Use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in a clinical trial in 3630 infants. Arch Dis Child 96(Suppl 1):A3\u2013A3","journal-title":"Arch Dis Child"},{"issue":"3","key":"2253_CR129","doi-asserted-by":"publisher","first-page":"i","DOI":"10.1093\/cid\/cit786","volume":"58","author":"Anonymous","year":"2014","unstructured":"Anonymous (2014) Princeton University can import vaccine to combat meningitis outbreak. Clin Infect Dis 58(3):i. (United States)","journal-title":"Clin Infect Dis"},{"key":"2253_CR130","unstructured":"Dull P, Pizza, M, Toneatto D, De Tora L, Ypma E, Kleinschmidt A, Kimura A (2010) Early clinical development of a novel, multicomponent meningococcal serogroup B vaccine (4CMenB). Can J Infect Dis Med Microbiol 21(4):183\u2013184"},{"issue":"4","key":"2253_CR131","first-page":"182","volume":"21","author":"P Dull","year":"2010","unstructured":"Dull P, Wang H, Annett Kleinschmidt A, Toneatto D, Kimura A, Dull P, Wang H (2010) Immunogenicity and safety of a recombinant meningococcal serogroup B vaccine and a quadrivalent conjugate vaccine in laboratory workers. Can J Infect Dis Med Microbiol 21(4):182\u2013183","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"4","key":"2253_CR132","first-page":"183","volume":"21","author":"S Esposito","year":"2010","unstructured":"Esposito S, Vesikari T, Kimura A, Ypma E, Toneatto D, Dull P (2010) Tolerability of a three-dose schedule of an investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. Can J Infect Dis Med Microbiol 21(4):183","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2253_CR133","first-page":"98","volume":"28","author":"M Thorel","year":"2014","unstructured":"Thorel M, Fummi C, Chavade D, Massy N, Dagostino C, Andr\u00e9jak M, Gras V (2014) A new signal of pharmacovigilance: persistent indurations with meningococcal B vaccine. Fundam Clin Pharmacol 28:98","journal-title":"Fundam Clin Pharmacol"},{"key":"2253_CR134","unstructured":"Vesikari TE, Esposito S, Kimura A, Kleinschmidt A, Ypma, E, Toneatto D, Dull P (2010) Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. Can J Infect Dis Med Microbiol 21(4):183"},{"key":"2253_CR135","doi-asserted-by":"crossref","unstructured":"Vesikari TE, Esposito S, Prymula R, Ypma, E, Kleinschmidt, A, Toneatto D, Kimura A, Dull P (2011) Use of an investigational multicomponent meningococcal serogroup B vaccine (4cmenb) in a clinical trial in 3630 infants. Arch Dis Child 96:3","DOI":"10.1136\/adc.2011.212563.6"},{"issue":"9869","key":"2253_CR136","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"TE Vesikari","year":"2013","unstructured":"Vesikari TE, Esposito S, Prymula R (2013) Erratum: Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. (Lancet (2013) 381 (825\u2013836)). Lancet 381(9869):804","journal-title":"Lancet"},{"issue":"5","key":"2253_CR137","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4155\/cli.12.41","volume":"2","author":"J Wassil","year":"2012","unstructured":"Wassil J, McIntosh EDG, Serruto D, DeTora L, Br\u00f6ker M, Kimura A (2012) The early clinical development of a multicomponent vaccine against meningococcal serogroup B. Clin Investig 2(5):503\u2013517","journal-title":"Clin Investig"},{"key":"2253_CR138","unstructured":"De Serres G, Gari\u00e9py M-C, Billard M-N, Rouleau I, Buolianne N, Toth E, Gagn\u00e9 H, Bilodeau C, Dub\u00e9 E, Vivion M et al (2014) Preliminary surveillance report on the safety of meningococcal serogroup B vaccination in Saguenay\u2014Lac-Saint-Jean. Abstract and Poster at the Canadian Immunization Conference 2014. Ottawa"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-015-2253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-015-2253-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-015-2253-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-015-2253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:54:19Z","timestamp":1744174459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-015-2253-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":138,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s00103-015-2253-z","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"type":"print","value":"1436-9990"},{"type":"electronic","value":"1437-1588"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}